Metachromatic Leukodystrophy
Neurology · Specialty and rare-disease access
About Metachromatic Leukodystrophy
A rare inherited metabolic disorder affecting nerve cell myelin.
Access to specialty treatment
Patients with Metachromatic Leukodystrophy living in countries where their prescribed treatment is not registered or not reimbursed can explore Named Patient Program access. Reserve Meds coordinates this pathway: we work with your physician, help prepare destination-country documentation, and source the drug from DSCSA-compliant US wholesalers.
What to discuss with your physician
- Whether a specific US-approved drug is clinically appropriate for your case.
- Whether your treating physician can issue a prescription for NPP access.
- What documentation your destination country requires for the specific drug.
- Any dose, monitoring, or administration considerations.